Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups, a top executive told Reuters.

Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India

Catalent

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent , saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs.

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Eli Lilly

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

2 No-Brainer Dividend Growth Stocks to Buy Right Now

Celsius Holdings

Dell Technologies

These stocks are all down 14% or more in the past three months.

Got $5,000? These 3 Growth Stocks Are on Sale Right Now.

Novo Nordisk (NVO) closed the most recent trading day at $117.20, moving -0.48% from the previous trading session.

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors

Bagsværd, Denmark, 8 October 2024 – Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together with a coalition of partners such as city governments, academic institutions and non-profit organisations, the initiative will support six cities in designing, implementing and evaluating tailored solutions focused on physical activity and healthy eating.

Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities

Bagsværd, Denmark, 7 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Novo Nordisk A/S – Share repurchase programme

Jefferies has downgraded its rating on Novo Nordisk (NYSE:NVO) to "underperform" and cut its price target to DKK 575, down from the previous DKK 782.90. The downgrade comes amid concerns over the supply of the Danish drugs giant's weight-loss drug, Wegovy, particularly in the United States, where prescriptions for the 0.25 mg starter dose have dropped significantly.

Novo Nordisk downgraded amid supply bottlenecks

Regeneron Pharmaceuticals

Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications.

Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)

Visa

These companies have been on fire for a while, but they haven't peaked yet.

Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030

Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production globally, the firm said on Friday.

Novo Nordisk to invest $158 million in insulin plant in Brazil

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter.

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem.

Analysts from Citi are bullish about the GLP-1 market, particularly within obesity and diabetes treatments, signaling a positive outlook for key players despite facing some supply constraints. According to Citi, there was an impressive 244% increase in total prescriptions for obesity drugs, such as Wegovy, and an 18% rise for diabetes medications, including Ozempic and Rybelsus.

Wegovy and Ozempic drive impressive prescription growth, says Citi

Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.

Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years

ASML Hld

Infineon Technologies AG

U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated. Generally, a lower federal funds rate is often a boon for stocks, as businesses are able to more easily secure loans to facilitate growth and consumers may be more likely to increase spending habits.

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Pfizer

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?

PFE vs. NVO: Which Stock Is the Better Value Option?

Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.

Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales

It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs.

Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?

Evotec SE

On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?

Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.

Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.

Evotec and Novo Nordisk forge technology development partnership

Some experts believe Novo Nordisk A/S  NVO products not only help people lose weight and control diabetes, they can help treat the country's addiction crisis.

Lose Weight With Novo Nordisk Drugs, Gain Money With Stock

Novo Nordisk's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study. The results suggest semaglutide, the active ingredient in Ozempic, could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.

News for Novo Nordisk Stock (NVO)